Find similar content

Source channel @githubtrending · Post #15057 · Aug 14

#go#external_secrets#hacktoberfest#kubernetes#kubernetes_secrets#secrets_manager External Secrets Operator (ESO) is a Kubernetes tool that connects external secret managers like AWS Secrets Manager, HashiCorp Vault, and others to Kubernetes, automatically injecting secret values into Kubernetes Secrets. However, official releases are paused because the current maintainer team is too small to support ongoing development and community help. You can still use the latest code from the main branch, but no new official versions or support will be provided until more maintainers join. If your team relies on ESO, contributing helps keep the project healthy and ensures future updates. This pause highlights the importance of community support for open-source tools you depend on. Using ESO benefits you by simplifying secure secret management in Kubernetes across multiple cloud providers. https://github.com/external-secrets/external-secrets

Hashtags

#go #external_secrets #hacktoberfest #kubernetes #kubernetes_secrets #secrets_manager

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选

Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

Find similar View

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Hashtags

#hongkong #pharmaceuticals #biotech #innovation #stockmarket #healthcare #drugdevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

Find similar View

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

Hashtags

#biotech #funding #cancer #immunedisorders #california #clinicalstage #therapies #investment #healthcare #innovation #pepromenebio #pharmaceuticals #medicalresearch #drugdevelopment